< Zurück zu den aktuellen Neuigkeiten & Events

Articles

Co-Existence Agreements – The importance of getting them right

Juni 2020

A co-existence agreement allows businesses to trade using the same (or similar) mark, but with certain agreed restrictions, such as geographical constraints where a mark can be used. For example – one party may be able to sell under the mark in Europe, and another can sell under the mark in the USA. The need for this may arise for example where two parties have unknowingly adopted the same mark at the same time.

The recent case of Merck KGaA v Merck Sharp & Dohme Corp and Ors [2020] EWHC 1273 (Ch) concerned a long running trade mark dispute between Merck KGaA (Merck Global) and Merck Sharp & Dohme Corporation (Merck US) and illustrates the importance of making sure co-existence agreements are fit for purpose.

Background

Merck Global was founded in 1688 in Germany. A US subsidiary was established that subsequently became an independent company. A co-existence agreement was entered into in 1955 and then updated in 1970, which set out the parties use of the mark ‘Merck’. This agreement provided that Merck US were fine to use this mark in the US and Canada, however in other countries they would use ‘Merck Sharp & Dohme’ (the company’s full name).

Infringement

Merck Global claimed that online and offline uses of ‘Merck’ in the UK by Merck US breached the co-existence agreement between the parties. In 2016, the High Court found that Merck US’ use of the mark in the UK constituted a breach of the co-existence agreement. Merck US appealed, and the Court of Appeal found in 2017 that Merck US had breached the agreement. The issues of whether these breaches constituted trade mark infringement were referred back to the High Court.

The judge found that Merck US’ use of the mark on websites, email addresses and social media targeted at the UK could constitute “use in the course of trade” (i.e. – physical goods do not actually have to be available, given the fact that Merck US had used a different mark on products actually sold in the UK) and accordingly use in this way constituted trade mark infringement. An injunction was granted against Merck US to prevent it from infringing the mark in the UK.

How can a business get this right?

Ensuring that a co-existence agreement will adequately deal with every eventuality that may arise in the future is obviously impossible. However, the co-existence agreement in this instance appeared to be very simple and had not been updated since 1970 (and consequently could never deal with issues such as whether use on social media constituted infringement). Parties to such an agreement should therefore think about the following;

  • What effect could rapidly evolving technology have on the use of a mark in future. Could this widen the use of a mark, sometimes inadvertently beyond the scope of what was originally intended?
  • Where do you realistically intend to sell products? Basing an agreement on current markets and ignoring potential markets could cause problems down the line.
  • Include adequate dispute resolution processes (for example a requirement to mediate a dispute) in order to hopefully avoid costly and lengthy litigation.
  • Given this case and the effects of the internet and other technology, it may be worthwhile introducing requirements for the agreement to be reviewed (for example every ten years) to make sure it adequately provides for such advancements or changes to the parties’ businesses
  • Don’t just consider geography – consider all elements of hard copy and electronic use including social media, websites, physical marketing brochures and other advertising materials.

This article was prepared by HGF Senior IP Solicitor Chris Robinson. If you would like further advice on this or any other matter, please contact Chris.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Weiterlesen

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Weiterlesen
Event - 14. Januar 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Veranstaltungsdetails

Personal names as 'brands' in the world of fashion

Episode 1 Personal names as ‘brands’ in the world of fashion    

Weiterlesen

Colour in fashion and the difficulties of protecting it

Episode 2 Colour in fashion and the difficulties of protecting it  

Weiterlesen

Trade marks which are fashion products, and fashion products which are trade marks

Episode 3 Trade marks which are fashion products, and fashion products which are trade marks

Weiterlesen

Zombie Fashion Brands

Episode 4 Zombie Fashion Brands  

Weiterlesen

Trade mark rights protecting fashion designs

Episode 5 Trade mark rights protecting fashion designs

Weiterlesen